Ascvd clinical trials

Explore recruiting ascvd clinical trials.

Recruiting ascvd studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Ascvd trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event

Greece, Hungary, Poland, Germany, Slovakia, Denmark +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk

Denmark

Phase III and phase IV (Integrated) EU CTIS Study details

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)

Slovakia, Poland, Greece, Netherlands, Germany, Czechia +16 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation

Denmark, Lithuania, Netherlands, Hungary, Poland, Bulgaria +12 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Impact of GLP1-RAs on inflammation and endothelial biomarkerS in Type 2 diABetes meLlitus patiEnts: STABLE-GLP1 trial.

Italy

Therapeutic use (Phase IV) EU CTIS Study details

IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WITH ULCERATIVE COLITIS

France

Phase III and phase IV (Integrated) EU CTIS Study details

Ascvd trials by city

Ascvd in Toronto Ascvd in Vancouver Ascvd in Montreal Ascvd in Calgary Ascvd in Edmonton Ascvd in Ottawa Ascvd in Winnipeg Ascvd in Quebec City Ascvd in Hamilton Ascvd in Kitchener Ascvd in London Ascvd in Halifax Ascvd in New York Ascvd in Los Angeles Ascvd in Chicago Ascvd in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease